Arcturus Therapeutics ARCT 深 滬
已收盤 11-14 16:00:00 美东时间
7.27
-0.500
-6.44%
華盛通- 最 高7.65
- 今 開7.44
- 成交量 112.69万股
- 最 低 7.26
- 昨 收 7.77
- 總市值 1.97亿
- 52周最高 24.17
- 市盈率 靜 --
- 換手率 4.15%
- 52周最低 7.26
- 委 比 52.37%
- 總股本 2715.45万
- 歷史最高 129.71
- 量 比 1.17
- 振 幅 5.02%
- 歷史最低 4.11
- 每 手 1
- 風險率 3.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
HC Wainwright & Co. Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9
HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.
11-12 00:27
Arcturus Therapeutics Q3 EPS $(0.49) Beats $(0.90) Estimate, Sales $17.151M Miss $21.196M Estimate
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.90) by 45.49 percent. This is a 88.46 percent decrease over losses of $(0.26) per share
11-11 05:01
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
华尔街顶级分析师最新研判：Coinbase、eBay获评级上调
华尔街最受关注、对市场走势有影响的研究评级报告现已汇总。以下是由 The Fly 整理的今日投资者需重点关注的研报观点。 五大评级上调个股 eBay（股...
10-24 23:00
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
New Phase 3 data demonstrate that ZORYVE cream effectively reduces sleep disruptions and improves quality of life for individuals with atopic dermatitis aged ≥2 years. The study highlights that ZORYVE cream, used once daily, significantly decreased itching and improved sleep quality in both adults and children, with minimal adverse effects. Additionally, long-term data show sustained disease control and reduced affected body surface area when swi...
10-24 12:00
美股大行评级 | 上调目标价！特斯拉、赛默飞世尔、拉姆研究、波士顿科学、安诺电子、金沙集团等获众多机构评级
今日重点评级关注：摩根士丹利：维持Viking Therapeutics"超配"评级，目标价从98美元升至102美元；摩根大通：维持IDEAYA Biosciences"超配"评级，目标价从74美元升至79美元
10-24 09:51
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
